SH PHARMA (02607) Income Statement & Earnings

11.820
-0.040-0.34%

Market Closed Apr 24 16:07 CST

43.83BMarket Cap6.92P/E (TTM)

SH PHARMA (02607) Income Statement

All

YOY

Hide blank lines

(FY)Dec 31, 2025

(Q9)Sep 30, 2025

(Q6)Jun 30, 2025

(Q1)Mar 31, 2025

(FY)Dec 31, 2024

(Q9)Sep 30, 2024

(Q6)Jun 30, 2024

(Q1)Mar 31, 2024

(FY)Dec 31, 2023

(Q9)Sep 30, 2023

Turnover

3.03%283.58B

2.60%215.07B

1.56%141.59B

0.87%70.76B

5.75%275.25B

6.14%209.63B

5.14%139.41B

5.93%70.15B

12.21%260.3B

13.11%197.51B

Operating income

3.03%283.58B

2.60%215.07B

1.56%141.59B

0.87%70.76B

5.75%275.25B

6.14%209.63B

5.14%139.41B

5.93%70.15B

12.21%260.3B

13.11%197.51B

Operating expenses

-3.49%-253.16B

-3.33%-192.65B

-2.77%-126.66B

-2.22%-63.51B

-6.84%-244.62B

-7.44%-186.45B

-6.67%-123.25B

-7.87%-62.12B

-13.63%-228.97B

-14.22%-173.55B

Gross profit

-0.70%30.42B

-3.27%22.42B

-7.64%14.93B

-9.61%7.26B

-2.22%30.63B

-3.28%23.18B

-5.22%16.17B

-7.03%8.03B

2.76%31.33B

5.67%23.96B

Selling expenses

-3.87%-13.21B

1.70%-9.32B

6.09%-6.16B

16.11%-2.76B

8.55%-12.71B

9.46%-9.48B

15.10%-6.57B

15.86%-3.29B

2.64%-13.9B

-1.29%-10.47B

Administrative expenses

6.63%-5.31B

-0.65%-4.17B

7.21%-2.66B

4.81%-1.32B

0.38%-5.69B

1.22%-4.14B

-3.86%-2.87B

-0.90%-1.39B

-14.43%-5.71B

-11.62%-4.19B

Research and development expenses

2.27%-2.34B

6.23%-1.52B

13.22%-958.95M

0.88%-497.02M

-8.64%-2.39B

-10.09%-1.62B

-7.67%-1.11B

7.26%-501.45M

-4.35%-2.2B

-5.70%-1.47B

Profit from asset sales

-16.39%157.15M

9.78%160.09M

-71.30%39.99M

-100.82%-903.05K

103.26%187.97M

39.44%145.83M

88.91%139.31M

405.21%110.04M

-93.57%92.48M

-92.67%104.58M

Revaluation surplus

62.92%332.12M

-20.44%113.14M

-33.72%75.75M

-27.65%37.8M

-49.63%203.85M

-40.51%142.2M

-41.94%114.29M

-41.55%52.25M

85.03%404.73M

225.04%239.02M

-Changes in the fair value of other assets

62.92%332.12M

-20.44%113.14M

-33.72%75.75M

-27.65%37.8M

-49.63%203.85M

-40.51%142.2M

-41.94%114.29M

-41.55%52.25M

85.03%404.73M

225.04%239.02M

Impairment and provision

-89.55%-1.59B

-184.57%-1.41B

-152.91%-834.05M

8.25%-221.85M

0.08%-840.54M

-89.25%-496.97M

-22.04%-329.78M

-42.34%-241.8M

-30.64%-841.24M

-15.91%-262.6M

-Other impairment is provision

-89.55%-1.59B

-184.57%-1.41B

-152.91%-834.05M

8.25%-221.85M

0.08%-840.54M

-89.25%-496.97M

-22.04%-329.78M

-42.34%-241.8M

-30.64%-841.24M

-15.91%-262.6M

Special items of operating profit

269.53%3.75B

458.59%3.81B

829.71%3.57B

0.94%235.46M

39.96%1.01B

96.95%682.34M

124.15%384.1M

-34.56%233.27M

-21.78%725.04M

-49.72%346.45M

Operating profit

17.96%11.35B

20.90%9.45B

36.96%7.58B

-9.61%2.52B

5.12%9.62B

1.40%7.82B

3.86%5.54B

-4.11%2.79B

-11.38%9.15B

-10.54%7.71B

Financing income

22.48%-404.97M

-25.62%270.23M

31.31%-176.38M

-38.73%83.49M

-13.11%-522.39M

1.84%363.3M

-20.80%-256.78M

25.24%136.28M

-5.37%-461.83M

5.04%356.74M

Financing cost

9.20%-1.69B

7.65%-1.28B

3.28%-887.69M

5.85%-444.08M

1.50%-1.86B

5.10%-1.39B

4.64%-917.77M

4.13%-471.67M

-11.59%-1.88B

-18.90%-1.46B

Special items of earning before tax

-1.30%-122.28M

-58.56%-38.67M

-44.19%-12.8M

213.51%6.33M

80.31%-120.71M

34.01%-24.39M

63.46%-8.88M

54.93%2.02M

-197.11%-612.94M

30.84%-36.96M

Earning before tax

22.44%9.82B

24.89%8.3B

41.45%6.82B

-10.92%2.15B

13.69%8.02B

1.92%6.64B

6.36%4.82B

-3.02%2.42B

-19.91%7.05B

-13.86%6.52B

After-tax profit from continuing operations

18.80%6.97B

19.17%5.99B

38.85%4.99B

-12.08%1.64B

13.62%5.87B

1.40%5.02B

5.28%3.6B

-4.48%1.87B

-26.11%5.17B

-17.22%4.95B

Earning after tax

18.80%6.97B

19.17%5.99B

38.85%4.99B

-12.08%1.64B

13.62%5.87B

1.40%5.02B

5.28%3.6B

-4.48%1.87B

-26.11%5.17B

-17.22%4.95B

Minority profit

-5.19%1.25B

-13.42%839.08M

-18.24%535.92M

-5.00%307.12M

-5.80%1.32B

-16.24%969.12M

-18.80%655.45M

-25.75%323.29M

1.72%1.4B

-1.14%1.16B

Profit attributable to shareholders

25.74%5.72B

26.96%5.15B

51.56%4.46B

-13.56%1.33B

20.82%4.55B

6.78%4.05B

12.72%2.94B

1.62%1.54B

-32.92%3.77B

-21.13%3.8B

Basic earnings per share

25.20%1.54

27.52%1.39

51.90%1.2

-14.29%0.36

20.59%1.23

5.83%1.09

11.27%0.79

2.44%0.42

-36.65%1.02

-28.97%1.03

Diluted earnings per share

25.20%1.54

27.52%1.39

51.90%1.2

-14.29%0.36

20.59%1.23

5.83%1.09

11.27%0.79

2.44%0.42

-36.65%1.02

-28.97%1.03

Currency Unit

CNY

Accounting Standards

CAS (2007)

Audit Opinions

Unqualified Opinion

Auditor

Deloitte Touche Tohmatsu Certified Public Accountants (Special General Partnership)

PwC Zhongtian Certified Public Accountants (Special General Partnership)

	(FY)Dec 31, 2025	(Q9)Sep 30, 2025	(Q6)Jun 30, 2025	(Q1)Mar 31, 2025	(FY)Dec 31, 2024	(Q9)Sep 30, 2024	(Q6)Jun 30, 2024	(Q1)Mar 31, 2024	(FY)Dec 31, 2023	(Q9)Sep 30, 2023
Turnover	3.03%283.58B	2.60%215.07B	1.56%141.59B	0.87%70.76B	5.75%275.25B	6.14%209.63B	5.14%139.41B	5.93%70.15B	12.21%260.3B	13.11%197.51B
Operating income	3.03%283.58B	2.60%215.07B	1.56%141.59B	0.87%70.76B	5.75%275.25B	6.14%209.63B	5.14%139.41B	5.93%70.15B	12.21%260.3B	13.11%197.51B
Operating expenses	-3.49%-253.16B	-3.33%-192.65B	-2.77%-126.66B	-2.22%-63.51B	-6.84%-244.62B	-7.44%-186.45B	-6.67%-123.25B	-7.87%-62.12B	-13.63%-228.97B	-14.22%-173.55B
Gross profit	-0.70%30.42B	-3.27%22.42B	-7.64%14.93B	-9.61%7.26B	-2.22%30.63B	-3.28%23.18B	-5.22%16.17B	-7.03%8.03B	2.76%31.33B	5.67%23.96B
Selling expenses	-3.87%-13.21B	1.70%-9.32B	6.09%-6.16B	16.11%-2.76B	8.55%-12.71B	9.46%-9.48B	15.10%-6.57B	15.86%-3.29B	2.64%-13.9B	-1.29%-10.47B
Administrative expenses	6.63%-5.31B	-0.65%-4.17B	7.21%-2.66B	4.81%-1.32B	0.38%-5.69B	1.22%-4.14B	-3.86%-2.87B	-0.90%-1.39B	-14.43%-5.71B	-11.62%-4.19B
Research and development expenses	2.27%-2.34B	6.23%-1.52B	13.22%-958.95M	0.88%-497.02M	-8.64%-2.39B	-10.09%-1.62B	-7.67%-1.11B	7.26%-501.45M	-4.35%-2.2B	-5.70%-1.47B
Profit from asset sales	-16.39%157.15M	9.78%160.09M	-71.30%39.99M	-100.82%-903.05K	103.26%187.97M	39.44%145.83M	88.91%139.31M	405.21%110.04M	-93.57%92.48M	-92.67%104.58M
Revaluation surplus	62.92%332.12M	-20.44%113.14M	-33.72%75.75M	-27.65%37.8M	-49.63%203.85M	-40.51%142.2M	-41.94%114.29M	-41.55%52.25M	85.03%404.73M	225.04%239.02M
-Changes in the fair value of other assets	62.92%332.12M	-20.44%113.14M	-33.72%75.75M	-27.65%37.8M	-49.63%203.85M	-40.51%142.2M	-41.94%114.29M	-41.55%52.25M	85.03%404.73M	225.04%239.02M
Impairment and provision	-89.55%-1.59B	-184.57%-1.41B	-152.91%-834.05M	8.25%-221.85M	0.08%-840.54M	-89.25%-496.97M	-22.04%-329.78M	-42.34%-241.8M	-30.64%-841.24M	-15.91%-262.6M
-Other impairment is provision	-89.55%-1.59B	-184.57%-1.41B	-152.91%-834.05M	8.25%-221.85M	0.08%-840.54M	-89.25%-496.97M	-22.04%-329.78M	-42.34%-241.8M	-30.64%-841.24M	-15.91%-262.6M
Special items of operating profit	269.53%3.75B	458.59%3.81B	829.71%3.57B	0.94%235.46M	39.96%1.01B	96.95%682.34M	124.15%384.1M	-34.56%233.27M	-21.78%725.04M	-49.72%346.45M
Operating profit	17.96%11.35B	20.90%9.45B	36.96%7.58B	-9.61%2.52B	5.12%9.62B	1.40%7.82B	3.86%5.54B	-4.11%2.79B	-11.38%9.15B	-10.54%7.71B
Financing income	22.48%-404.97M	-25.62%270.23M	31.31%-176.38M	-38.73%83.49M	-13.11%-522.39M	1.84%363.3M	-20.80%-256.78M	25.24%136.28M	-5.37%-461.83M	5.04%356.74M
Financing cost	9.20%-1.69B	7.65%-1.28B	3.28%-887.69M	5.85%-444.08M	1.50%-1.86B	5.10%-1.39B	4.64%-917.77M	4.13%-471.67M	-11.59%-1.88B	-18.90%-1.46B
Special items of earning before tax	-1.30%-122.28M	-58.56%-38.67M	-44.19%-12.8M	213.51%6.33M	80.31%-120.71M	34.01%-24.39M	63.46%-8.88M	54.93%2.02M	-197.11%-612.94M	30.84%-36.96M
Earning before tax	22.44%9.82B	24.89%8.3B	41.45%6.82B	-10.92%2.15B	13.69%8.02B	1.92%6.64B	6.36%4.82B	-3.02%2.42B	-19.91%7.05B	-13.86%6.52B
After-tax profit from continuing operations	18.80%6.97B	19.17%5.99B	38.85%4.99B	-12.08%1.64B	13.62%5.87B	1.40%5.02B	5.28%3.6B	-4.48%1.87B	-26.11%5.17B	-17.22%4.95B
Earning after tax	18.80%6.97B	19.17%5.99B	38.85%4.99B	-12.08%1.64B	13.62%5.87B	1.40%5.02B	5.28%3.6B	-4.48%1.87B	-26.11%5.17B	-17.22%4.95B
Minority profit	-5.19%1.25B	-13.42%839.08M	-18.24%535.92M	-5.00%307.12M	-5.80%1.32B	-16.24%969.12M	-18.80%655.45M	-25.75%323.29M	1.72%1.4B	-1.14%1.16B
Profit attributable to shareholders	25.74%5.72B	26.96%5.15B	51.56%4.46B	-13.56%1.33B	20.82%4.55B	6.78%4.05B	12.72%2.94B	1.62%1.54B	-32.92%3.77B	-21.13%3.8B
Basic earnings per share	25.20%1.54	27.52%1.39	51.90%1.2	-14.29%0.36	20.59%1.23	5.83%1.09	11.27%0.79	2.44%0.42	-36.65%1.02	-28.97%1.03
Diluted earnings per share	25.20%1.54	27.52%1.39	51.90%1.2	-14.29%0.36	20.59%1.23	5.83%1.09	11.27%0.79	2.44%0.42	-36.65%1.02	-28.97%1.03
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)
Audit Opinions	--	--	--	--	Unqualified Opinion	--	--	--	Unqualified Opinion	--
Auditor	--	--	--	--	Deloitte Touche Tohmatsu Certified Public Accountants (Special General Partnership)	--	--	--	PwC Zhongtian Certified Public Accountants (Special General Partnership)	--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"